Qiagen NV (QGEN) FinancialsQGENQiagen NV

QIAGEN N.V. (QGEN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Consumables and Related Revenues, accounting for 90.3% of total sales, equivalent to $445.00M. Another important revenue stream is Instrumentation. Understanding this composition is critical for investors evaluating how QGEN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, QIAGEN N.V. maintains a gross margin of 63.28%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 26.43%, while the net margin is 16.69%. These profitability ratios, combined with a Return on Equity (ROE) of 11.93%, provide a clear picture of how effectively QGEN converts its operational activities into shareholder value.

In the context of the broader market, QGEN competes directly with industry leaders such as BIO and GKOS. With a market capitalization of $9.43B, it holds a significant position in the sector. When comparing efficiency, QGEN's gross margin of 63.28% stands against BIO's 53.12% and GKOS's 81.67%. Such benchmarking helps identify whether QIAGEN N.V. is trading at a premium or discount relative to its financial performance.

Qiagen reported a gross margin of 63.28% in Q2 2026, reflecting strong profitability. The net income for Q2 2026 was $103.4 million, showing solid earnings performance. The forward P/E ratio of 13.53 suggests the stock is reasonably priced given its earnings potential.